CRISPR Therapeutics (CRSP) Stock Overview
A gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
CRSP Community Fair Values
Create NarrativeSee what 196 others think this stock is worth. Follow their fair value or set your own to get alerts.
CRISPR Therapeutics AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$64.76 |
| 52 Week High | US$71.13 |
| 52 Week Low | US$30.04 |
| Beta | 1.82 |
| 1 Month Change | 35.88% |
| 3 Month Change | 69.22% |
| 1 Year Change | 11.81% |
| 3 Year Change | -13.65% |
| 5 Year Change | -24.22% |
| Change since IPO | 359.62% |
Recent News & Updates
Crispr Therapeutics: Shares Are Soaring - This Could Be The Start Of Something Big
Jul 23CRISPR Therapeutics (NASDAQ:CRSP) Is In A Good Position To Deliver On Growth Plans
Mar 27
CRISPR Therapeutics: An Uninspiring Start For Casgevy
Mar 14Recent updates
Crispr Therapeutics: Shares Are Soaring - This Could Be The Start Of Something Big
Jul 23CRISPR Therapeutics (NASDAQ:CRSP) Is In A Good Position To Deliver On Growth Plans
Mar 27CRISPR Therapeutics: An Uninspiring Start For Casgevy
Mar 14Crispr Therapeutics Q4 Earnings Review: Ignore The Lack Of Revenues, Buy The Future
Feb 13CRISPR Therapeutics: Unfairly Punished By The Issues Of Its Peers
Jan 16CRISPR Therapeutics AG's (NASDAQ:CRSP) Share Price Not Quite Adding Up
Dec 31Crispr Therapeutics: From Casgevy Success To A Catalyst-Rich 2025
Dec 29Here's Why We're Not Too Worried About CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn Situation
Dec 03Crispr Therapeutics Q3 Earnings: No Casgevy Revenue, But Plenty Of Optimism
Nov 11Here's What Analysts Are Forecasting For CRISPR Therapeutics AG (NASDAQ:CRSP) After Its Third-Quarter Results
Nov 07Crispr Therapeutics: Poised For A Major Turnaround
Oct 28CRISPR Therapeutics AG (NASDAQ:CRSP) Investors Are Less Pessimistic Than Expected
Oct 02Crispr Therapeutics: Casgevy Now Active Across 35 Treatment Centres
Sep 13Here's Why We're Not At All Concerned With CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn Situation
Sep 04Crispr's Casgevy Launch: Promising Start, Uncertain Future
Aug 14A Look At The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)
Aug 09Crispr Therapeutics Q2 Earnings: Casgevy Updates Underline 'Blockbuster' Potential
Aug 07Crispr Therapeutics Remains Expensive, With Slower Casgevy Monetization And Patent Battle
Jul 13Crispr Therapeutics: Beaten Down But Not Broken
Jul 07Crispr Therapeutics, Futurism-Turning-Commercial, Defies 'Valuation' (Technical Analysis)
Jun 10Crispr Therapeutics' Strategic Moves Amidst Gene Therapy Challenges (Rating Upgrade)
Jun 03Crispr Therapeutics Q1 Earnings: Casgevy Launch Tip Of Gene Editing Iceberg
May 09Crispr Therapeutics: Market Misunderstanding Is Your Buying Opportunity (Upgrade)
May 03Crispr Therapeutics: Now Is The Time To Buy
Apr 24Crispr Therapeutics: CASGEVY Commercial Launch Is Taking Shape
Mar 26Crispr Therapeutics: Cautiously Optimistic
Feb 22Crispr Therapeutics: Investors Bet Against Casgevy Uptake
Feb 01Crispr Therapeutics: Commercial Validation Is The Next Step
Jan 18Impact Of Gene Therapies And Casgevy On Crispr AG And The Industry
Jan 11Shareholder Returns
| CRSP | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -0.6% | 3.2% | 1.4% |
| 1Y | 11.8% | -11.7% | 17.2% |
Return vs Industry: CRSP exceeded the US Biotechs industry which returned -11.7% over the past year.
Return vs Market: CRSP underperformed the US Market which returned 17.2% over the past year.
Price Volatility
| CRSP volatility | |
|---|---|
| CRSP Average Weekly Movement | 9.4% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CRSP has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: CRSP's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 393 | Sam Kulkarni | www.crisprtx.com |
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company’s CRISPR/Cas9 is a revolutionary technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting glypican-3 (GPC3) for the potential treatment of solid tumors.
CRISPR Therapeutics AG Fundamentals Summary
| CRSP fundamental statistics | |
|---|---|
| Market cap | US$6.06b |
| Earnings (TTM) | -US$385.66m |
| Revenue (TTM) | US$37.68m |
Is CRSP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CRSP income statement (TTM) | |
|---|---|
| Revenue | US$37.68m |
| Cost of Revenue | US$437.76m |
| Gross Profit | -US$400.08m |
| Other Expenses | -US$14.43m |
| Earnings | -US$385.66m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.20 |
| Gross Margin | -1,061.93% |
| Net Profit Margin | -1,023.64% |
| Debt/Equity Ratio | 0% |
How did CRSP perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/25 16:41 |
| End of Day Share Price | 2025/07/25 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
CRISPR Therapeutics AG is covered by 48 analysts. 25 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jack Allen | Baird |
| Huidong Wang | Barclays |
| Konstantinos Biliouris | BMO Capital Markets Equity Research |